Frankie Fattorini

Experts disagree on whether DPIs or low emissions pMDIs are the way forward for effective, environmentally friendly inhalers. Credit: Pixel-Shot/Shutterstock In a bid to improve the pharma sector’s drive to cut down greenhouse emissions, several companies are advancing dry powder […]

Minister for Science Lord Vallance said Labour seek closer ties with commercial clinical industry to ignite innovation. Credit: Frankie Fattorini/GlobalData Lord Patrick Vallance has emphasised plans for a close collaboration between the government and private sector, in line with the

The Danish companies aim to jointly develop a GLP-1RA administered once a month. Credit: Kittyfly / Shutterstock Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist

Pfizer CEO Dr Albert Bourla presided over an exceptional Q3 amid financial decline and pressure from investor Starboard Value. Credit: Ververidis Vasilis / Shutterstock. Pfizer has reported strong revenues in its latest earnings report, noting increased revenues over Q3 2023

: SP-624 may treat depression in women by modulating the distinct female genetic profile. Credit: Prathankarnpap/Shutterstock Arrivo BioVentures’ SIRT6 activator SP-624 has been found to significantly reduce symptoms of major depressive disorder (MDD), but only in women. Steve Butts, Arrivo

J&J’s Darzalex-VRd can now be given to newly diagnosed MM patients eligible for ASCT. Credit: Michael Vi/Shutterstock The European label for Johnson and Johnson Innovation Medicine’s (J&J) Darzalex (daratumumab) has been expanded to include patients with newly diagnosed multiple myeloma

Self-amplifying vaccines promise extended efficacy with lower doses than their mRNA predecessors, but approvals have been slow to materialize. Credit: Javier Zayas Photography/ Getty Images A year after bursting onto the scene amid the RNA renaissance, scientific challenges and regulatory

Genevant LNP technology will provide a vehicle for Editas’ CRISPR/Cas12a gene therapy. Credit: ART-ur / Shutterstock. Editas Medicine and Genevant Sciences will collaborate to develop gene editing therapies, employing their respective CRISPR and LNP technologies under a nonexclusive licencing agreement.

The EPO ruling affirms bit.bio’s European patent for opti-ox, its proprietary stem cell engineering technology. Credit: Yavdat/ Shutterstock bit.bio has successfully defended the European patent for its opti-ox cell programming technology. After a hearing held on 25 September 2024, the

Hanmi will advance its cancer assets through MEDiC’s MCAT platform in return for upfront payments, along with $5m in funding. Credit: sonnim/ Shutterstock Leading Korean biopharma, Hanmi Pharmaceutical, has entered into a research collaboration and financing agreement with Silicon Valley